Ocaratuzumab
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) [1][2].
Product Specifications
CAS Number
1169956-08-4
Product Name Alternative
AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody
UNSPSC
12352203
Target
CD20
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ocaratuzumab.html
Purity
95.00
Solubility
H2O
Smiles
[Ocaratuzumab]
Molecular Weight
(145.38 kDa)
References & Citations
[1]Forero-Torres A, et, al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18 (5) :1395-403.|[2]Cheney CM, et, al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs. 2014 May-Jun;6 (3) :749-55.
Shipping Conditions
Blue Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682315-500 1x 500 µL
Collagen VII (LH7.2), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402336-100 1x 100 µL
TRAcP (Tartrate-Resistant Acid Phosphatase) (Hairy Cell Leukemia Marker) (ACP5/2336R), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
